Docking Analysis of 07 Anti-HCV Drugs with COVID-19 Main Protease PDB ID: 6LU7

Ajeet ^1, , Babita Aggarwal¹, Santosh Kumar Verma¹ and Ajeet Singh²

¹Faculty of Pharmaceutical Sciences, Motherhood University, Roorkee, India

²Department of Pharmaceutical Sciences, J. S. University, Shikohabad, India

Cite this paper:
Ajeet , Babita Aggarwal, Santosh Kumar Verma and Ajeet Singh. Docking Analysis of 07 Anti-HCV Drugs with COVID-19 Main Protease PDB ID: 6LU7. American Journal of Pharmacological Sciences. 2020; 8(2):21-25. doi: 10.12691/ajps-8-2-1

Abstract

07 anti-HCV drugs have been processed and observed by docking analysis for understanding the binding patteren of drugs with COVID-19 main protease PDB ID: 6LU7 for any possibilities of protease inhibition. For docking analysis PyRx- Python Prescription 0.8 was used. This analysis reveals that the essential amino acids involved in binding of anti-HCV drugs to COVID-19 main protease PDB ID: 6LU7 are Threonine (THR), Cysteine (CYS), Histidine (HIS), Methionine (MET) and Proline (PRO). After docking analysis it was observed that Ledipasvir may be act as COVID-19 main protease inhibitor despite of being anti-HCV and may further be used in the treatment of COVID-19 infection after having proper clinical proofs.

Keywords:
COVID-19 anti-HCV protease inhibition

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Al-Hazmi A. Challenges presented by MERS corona virus, and SARS corona virus to global health. Saudi J Biol Sci. 2016, 23(4), 507-511.
[2]	Abdo A. Elfiky. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sciences. 2020 248, 117477.
[3]	RCSB PDB - 6LU7: The crystal structure of COVID-19 main protease in complex with an inhibitor N3. https://www.rcsb.org/structure/6lu7. (accessed on 13 April 2020).
[4]	Gillian M Keating. Daclatasvir: A Review in Chronic Hepatitis C. Drugs2016, 76(14), 1381-1391.
[5]	Mohamed El Kassas, Tamer Elbaz, Enas Hafez, Mohamed Naguib Wifi, Gamal Esmat. Discovery and Preclinical Development of Dasabuvir for the Treatment of Hepatitis C Infection. Expert Opin Drug Discov2017, 12(6), 635-642.
[6]	Dennis J Cada, Anne P Kim, Danial E Baker. Elbasvir/Grazoprevir. Hosp Pharm. 2016, 51(8), 665-686.
[7]	Lesley J Scott. Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. Drugs. 2018, 78(2), 245-256.
[8]	Auda A Eltahla, Enoch Tay, Mark W Douglas, Peter A White. Cross-genotypic Examination of Hepatitis C Virus Polymerase Inhibitors Reveals a Novel Mechanism of Action for Thumb Binders, Antimicrob Agents Chemother. 2014, 58(12), 7215-7224.
[9]	Prajakta S Badri 1, Diana L Shuster 1, Sandeep Dutta 1, Rajeev M Menon. Clinical Pharmacokinetics of Ombitasvir. Clin Pharmacokinet. 2017, 56(10), 1103-1113.
[10]	Rajeev M Menon, Akshanth R Polepally, Amit Khatri, Walid M Awni, Sandeep Dutta. Clinical Pharmacokinetics of Paritaprevir. Clin Pharmacokinet. 2017, 56(10), 1125-1137.
[11]	Ajeet, Kumar A., Mishra A.K. Design, Synthesis and Pharmacological Evaluation of Sulfonamide Derivatives Screened Against Maximal Electroshock Seizure Test. Mol Biol. 2018, 7, 206.
[12]	Ajeet, Kumar A., Mishra A.K. Design, molecular docking, synthesis, characterization, biological activity evaluation (against MES model), in-silico biological activity spectrum (PASS analysis), toxicological and predicted oral rat LD 50 studies of novel sulphonamide derivatives. Front Biol. 2018, 13(6), 425-451.
[13]	Ajeet. In silico designing and characterization of Amiloride derivatives as ion channel modulator. Med Chem Res. 2013, 22, 1004-1010.
[14]	Ajeet, Verma M., Rani S., Kumar A. Antitarget Interaction, Acute Toxicity and Protein Binding Studies of Quinazolinedione Sulphonamides as GABA1 Antagonists. Indian J Pharm Sci2016, 78(1), 48-53.
[15]	Mills N. ChemDraw Ultra 10.0. J Am Chem Soc2006, 128(41), 13649-13650.